Anuh Pharma : Q4 2024 Financial Quarterly Report : YoY Sales Up 4.18 %, QoQ Down 4.77 %

The comprehensive analytics outlining the performance and outlook of Anuh Pharma Ltd.,”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at Anuh Pharma Ltd.,’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 4.18 %. However, it did see a marginal slip of -4.77 % from the previous quarter. Expenses decreased slightly by -2.32 % quarter-on-quarter, aligning with the annual rise of 1.11 %. Operating profit, while up 35.07 % compared to last year, faced a quarter-on-quarter dip of -19.88 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 2.68 %, but a shrinkage of -2.21 % sequentially. Other income fell by -22.74 % compared to the last quarter, despite an annual growth of 173.79 %. Interest expenses dropped significantly by -28.57 % from the previous quarter, yet the year-over-year increase remains at a moderate 400 %. Depreciation costs climbed by 1.36 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -7.47 %. Profit before tax grew annually by 53.62 % but saw a reduction from the preceding quarter by -22.09 %.
Tax expenses as a percentage of profits decreased slightly by -2.94 % compared to last year, with a more notable quarter-on-quarter decrease of -2.36 %. Net profit rose by 59.67 % year-on-year but witnessed a -19.62 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 59.38 % but a quarterly fall of -19.69 %. In summary, Anuh Pharma Ltd.,’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing Anuh Pharma Ltd.,’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 4.18 % year-on-year growth, although there was a slight dip of -4.77 % from the previous quarter. Expenses rose by 1.11 % compared to the previous year, with a decrease of -2.32 % quarter-on-quarter. Operating Profit surged by 35.07 % annually, and saw a -19.88 % decrease from the last quarter.
Net Profit showed yearly increase of 59.67 %, and experienced a -19.62 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 59.38 % annually, however dipped by -19.69 % compared to the last quarter. In essence, while Anuh Pharma Ltd., exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.